the aid library

LIST OPTIONS

Filter

5370

Sort by:

Direction:

Download (1277)

View PDF (2293)

Good Pharmacy Practice - Joint FIP/WHO Guidelines on Good Pharmacy Practice: Standards for Quality of Pharmacy Services

World Health Organization (WHO), International Pharmaceutical Federation (FIP) (2011) C_WHO

WHO Technical Report Series, No. 961, 2011, Annex 8 - These guidelines are intended to provide a description of ways in which pharmacists can improve access to health care, health promotion and the use of medicines on behalf of the patients they serve. The role of FIP is to provide leadership for na... more

Download (168)

View PDF (209)

Behavorial Health Departement - Primary Care Center and fireweed Treatment Guidelines for PTSD

Sorkin, J., Chaney, G., Garcia, M.,et al. (2006) C2

This treatment guideline is intended to assist clinicians in the Behavioral Health department in treatment planning and service delivery for patients with Post Traumatic Stress Disorder (PTSD). It may also assist clinicians treating patients who have some of the signs and symptoms of PTSD but who do... more

Download (544)

View PDF (676)

Second WHO Model List of Essential In Vitro Diagnostics

World Health Organization WHO (2019) C_WHO

The updated List of Essential Diagnostics contains 46 general tests that can be used for routine patient care as well as for the detection and diagnosis of a wide array of disease conditions, and 69 tests intended for the detection, diagnosis and monitoring of specific diseases. The List is divid... more

Download (432)

View PDF (940)

National Guidelines for HIV-1 Viral Load Laboratory Testing
recommended

Government of India, Ministry of Health and Family Welfare, National AIDS Control Organisation (NACO) (2018) C1

The National Guidelines for HIV-1 Viral Load Laboratory Testing support plans to scale up viral load (VL) testing to reach the 90-90-90 targets in India. This phased scale-up includes the setup of 70 additional VL testing laboratories nationally. These guidelines include laboratory design considerat... more

Download (322)

View PDF (127)

WHO guidelines on the use of chest imaging in COVID-19
recommended

World Health Organization WHO (2022) C_WHO

Updated 2022. This guide addresses the care pathway from presentation of the patient to a health facility to patient discharge. It considers different levels of disease severity, from asymptomatic individuals to critically ill patients. Accounting for variations in the benefits and harms of chest im... more

Download (631)

View PDF (350)

WHO operational handbook on tuberculosis: module 4: treatment: tuberculosis care and support
recommended

World Health Organization WHO (2022) C_WHO

The consolidated guidelines are complemented by an operational handbook which is designed to assist with implementation of the WHO recommendations by Member States, technical partners and others who are involved in the management of patients with DR-TB. The WHO Operational Handbook on Tuberculosis, ... more

Download (142)

View PDF (170)

COVID-19 and Violence Against Health-Care – Safer COVID-19 Response: Checklist for Health-Care Services

International Committee of the Red Cross ICRC (2020) C1

The Safer COVID-19 Response checklist has been produced for managers of health-care services, individual practitioners and health policymakers worried about the impact of violence against health-care workers, facilities and patients during the COVID-19 response. It provides a practical, actionable s... more

Download (99)

View PDF (120)

Corticosteroids for COVID-19

World Health Organization WHO (2020) C_WHO

WHO published guidance for clinicians and health care decision-makers on the use of corticosteroids in patients with COVID-19. We recommend systemic corticosteroids for the treatment of patients with severe and critical COVID-19. We suggest not to use corticosteroids in the treatment of patients ... more

Download (87)

View PDF (130)

Africa CDC Consortium for COVID-19 Vaccine Clinical Trials (CONCVACT)

African Union; Africa CDC Centres for Disease Control and Prevention (2020) C1

August 2020, The Africa Joint Continental Strategy for COVID-19 is underpinned by the need to limit transmission, prevent deaths and reduce associated harms. Participation by African nations in clinical trials is an essential step to ensure that sufficient data is generated on the safety and efficac... more

Download (134)

View PDF (145)

Use of chest imaging in COVID-19 (Arab Version)
recommended

World Health Organization WHO (2020) C_WHO

This rapid advice guide examines the evidence and makes recommendations for the use of chest imaging in acute care of adult patients with suspected, probable or confirmed COVID-19. Imaging modalities considered are radiography, computed tomography and ultrasound. This guide addresses the care pathwa... more

Download (211)

View PDF (267)

Review on palliative care with focus on 18 high tuberculosis priority countries

World Health Organization WHO, Regional Office of Europe (2021) C_WHO

Tuberculosis (‎TB)‎ is, and should be, a curable disease; however, each year significant numbers of patients acquire or develop drug-resistant TB, which has a much lower cure rate. Patients with drug-resistant TB have a high prevalence of symptoms; hence, staff caring for these patients should h... more

Download (196)

View PDF (258)

Hypertension Control Change Package

Centers for Disease Control and Prevention (CDC) (2020) C_CDC

second edition Included more self-measured blood pressure (SMBP)-focused content with tools and resources. Showcased more tools to find patients with potentially undiagnosed HTN. Added new strategies that focus on chronic kidney disease testing and identification.

Download (102)

View PDF (133)

Drug Regulation in Kenya

LEAP (2021) CC

Drug registration in Kenya started in 1982; the process mainly involves an evaluation committee at the Kenya Pharmacy and Poisons Board (PPB) that aims to approve products based on quality, safety and efficacy.

Download (184)

View PDF (221)

Psychosocial counselling and treatment adherence support for people affected by tuberculosis

The Union (2021) C1

The guide is suitable and can be used for the following audiences: 1. nurses and other trained healthcare workers who can use this manual as a self-study tool and then incorporate its guidance into their practice; 2. governmental and non-governmental employers of lay and professional TB treatment ... more

Download (84)

View PDF (332)

Chagas Clinical Research Platform

Drugs for Neglected Diseases Initiative DNDi Latin America (2022) CC

To support its R&D activities on Chagas disease, DNDi launched the Chagas Clinical Research Platform (CCRP). The platform brings together partners, experts, and stakeholders to provide support for evaluation and development of new treatments for Chagas disease. The patient-centred platform aims to f... more

Download (110)

View PDF (336)

Rabies vaccines and immunoglobulins: WHO position

World Health Organization WHO (2017) C_WHO

The new WHO recommendations for rabies immunization supersede the 2010 WHO position on pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP) for rabies. These updated recommendations are based on new evidence and directed by public health needs that are cost-, dose- and time-sparing... more

Download (92)

View PDF (78)

Strengthening countries’ capacities to adopt and adapt evidence-based guidelines: a handbook for guideline contextualization

World Health Organization WHO (2023) C_WHO

Trustworthy, evidence-based health guidelines form the basis of national policies affecting both patients and health-care workers. Emphasizing the link between robust evidence and people’s trust in their health systems, Dr Hans Henri P. Kluge, WHO Regional Director for Europe said at the launch ev... more

Download (245)

View PDF (329)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (22)

View PDF (18)

The Case for the Digital Transformation of Circulatory Health

World Heart Federation (2020) CC

This paper explores the angles and opportunities of digital health, with a look at digital innovation and its potential to support patients with circulatory diseases. In reviewing developments in the field, current applications as well as gaps, the paper aims to support policymakers in leveraging ... more

Download (50)

View PDF (31)

Monitoring asthma in children

Pijnenburg, M.W.; Baraldi, E.; Brand, P.L. et al. European Respiratory Journal (2015) CC

The goal of asthma treatment is to obtain clinical control and reduce future risks to the patient. To reach this goal in children with asthma, ongoing monitoring is essential. While all components of asthma, such as symptoms, lung function, bronchial hyperresponsiveness and inflammation, may exist i... more

National Guidelines for HIV-1 Viral Load Laboratory Testing recommended

WHO guidelines on the use of chest imaging in COVID-19 recommended

WHO operational handbook on tuberculosis: module 4: treatment: tuberculosis care and support recommended

Use of chest imaging in COVID-19 (Arab Version) recommended

National Guidelines for HIV-1 Viral Load Laboratory Testing
recommended

WHO guidelines on the use of chest imaging in COVID-19
recommended

WHO operational handbook on tuberculosis: module 4: treatment: tuberculosis care and support
recommended

Use of chest imaging in COVID-19 (Arab Version)
recommended